Best Cell & Gene Therapy CDMOs in Asia
· updated as new inspection, certificate, and trial data enters the platform
24
CDMOs tracked
24
Fully scored
7
With FDA records
16
FDA inspections
41
EMA/MHRA GMP certs
6
Warning letters
Cell and gene therapy manufacturing spans two adjacent product classes: living cell products (CAR-T, TCR, NK, stem cell therapies) and the viral vectors used to genetically modify them (AAV, lentiviral, adenoviral). The two are tightly coupled in ex vivo cell engineering — a lentiviral vector CDMO supplies the vector that a cell therapy CDMO uses to modify patient T cells for CAR-T. Sponsors running integrated programs benefit from CDMOs covering both, and the ranking below aggregates that combined view.
For platform-specific rankings, use the dedicated pages: <a href="/modality/cell-therapy">Cell Therapy CDMOs</a>, <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>, <a href="/modality/gene-therapy">Gene Therapy CDMOs</a> (vectors only, no cell processing).
FDA inspection outcomes across these CDMOs: 7 NAI (no action), 9 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: Denmark (18), United States (11), Germany (6), India (5), INDIA (5).
Last updated 2026-10-06. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
|
78.6 | 100.0 | 2 insp · 23 GMP | Available | 2 programs |
| 2 |
PB
Pharmaron Biologics
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
|
86.9 | 100.0 | 3 insp · 0 GMP | Available | 0 programs |
| 3 |
AJ
Ajinomoto Bio-Pharma Services
San Diego, CA · Osaka, JP
|
83.5 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 4 |
MN
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
|
83.3 | 99.6 | 1 insp · 6 GMP | Limited | 0 programs |
| 5 |
WB2
WuXi Biologics
Shanghai, CN · Wuxi, CN
|
82.9 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 6 |
LB
Lotte Biologics
Incheon, KR · Syracuse, NY
|
81.6 | 100.0 | 1 insp · 0 GMP | — | 0 programs |
| 7 |
GS
GenScript ProBio
Piscataway, NJ · Nanjing, CN
|
79.5 | 100.0 | — | Constrained | 0 programs |
| 8 |
SG
Syngene International
Bengaluru, India
|
78.5 | 96.3 | 2 insp · 0 GMP | — | 0 programs |
| 9 |
BC
Biocon Biologics
Bengaluru, India
|
77.6 | 97.1 | 4 insp · 2 GMP | — | 0 programs |
| 10 |
GZ
Genezen
Indianapolis, IN · Lexington, MA
|
71.5 | 85.8 | 3 insp · 0 GMP | Available | 0 programs |
| 11 |
IU
Indiana University Vector Production Facility
Indianapolis, IN
|
66.3 | — | — | — | 49 programs |
| 12 |
GenScript
Piscataway, NJ (US HQ); Nanjing, China (primary operations)
|
64.0 | — | — | — | 0 programs |
| 13 |
HG
Hitachi Global Life Solutions (CGT)
Yokohama, Japan
|
63.0 | — | — | — | 0 programs |
| 14 |
SM
Sumitomo Chemical Advanced Medical
Tokyo, JP
|
63.0 | — | — | — | 0 programs |
| 15 |
EA
Esco Aster
Singapore, Singapore
|
63.0 | — | — | — | 0 programs |
| 16 |
Minaris (WuXi Advanced Therapies)
Philadelphia, PA / Yokohama, Japan
|
60.5 | — | — | — | 0 programs |
| 17 |
HX
Helixmith
Seoul, KR
|
59.0 | — | — | — | 0 programs |
| 18 |
CTP
Cell Therapies Pty Ltd
Melbourne, Australia
|
59.0 | — | — | — | 0 programs |
| 19 |
SS
Singota Solutions
Bloomington, IN
|
59.0 | — | — | — | 0 programs |
| 20 |
TR
Takara Bio
Kusatsu, Shiga Prefecture, Japan
|
57.9 | — | — | — | 8 programs |
| 21 |
UB
uBriGene Biosciences
Shanghai, CN · Boston, MA
|
56.5 | — | — | — | 0 programs |
| 22 |
GC
Green Cross Cell
Yongin, KR
|
56.5 | — | — | — | 0 programs |
| 23 |
CH
CHA Medical & Bio Group
Seongnam, KR
|
56.5 | — | — | — | 0 programs |
| 24 |
IP
Intas Pharmaceuticals
Ahmedabad, India
|
51.4 | 45.5 | 0 insp · 5 GMP | — | 0 programs |
What to evaluate in a Cell & Gene Therapy CDMO
Integrated vs point-solution CDMO
Ex vivo cell therapy programs benefit from CDMOs handling both vector and cell processing under one roof. Point-solution CDMOs specialize deeper but add tech-transfer complexity.
Regulatory record by process class
Cell therapy and viral vector inspections are separately scoped. Verify the CDMO's inspection record on the specific process class your program will use.
Chain-of-identity + cold chain
Autologous cell therapy demands per-patient scheduling, batch-of-one tracking, and cold-chain logistics that CDMOs vary meaningfully on. Confirm the CDMO's chain-of-identity software and cryopreservation posture.
Commercial track record
For late-stage programs, CDMOs with commercial-approved cell or gene therapy products on file carry demonstrable posture that ranking algorithms only partially capture.
Regulatory landscape across PMDA (Japan), NMPA (China), MFDS (South Korea)
Asian biopharma manufacturing spans multiple national regulators. PMDA (Japan) is generally regarded as one of the most stringent in Asia, with GMP requirements broadly aligned with FDA and EMA. NMPA (China) has substantially strengthened its GMP framework over the past decade, and Chinese CDMOs increasingly hold FDA and EMA certifications alongside NMPA registration. MFDS (South Korea) certification is standard for Korean CDMOs. For sponsors supplying US or EU markets, the qualifying signal for an Asian CDMO is typically FDA and EMA inspection history on the specific facility — which the Signal Score's Quality Compliance pillar captures directly.
Which Asian CDMOs cover FDA (US) and EMA/MHRA (Europe) regulatory geographies?
Asian CDMOs with US FDA and European EMA/MHRA inspection history are qualified to supply global markets; those without cross-jurisdictional inspection posture are typically limited to their home-market regulatory scope. The Signal Score's Quality Compliance pillar includes FDA + EMA + MHRA data directly, so Asian CDMOs with cross-jurisdictional certification typically rank higher on this pillar than home-market-only competitors. Sponsors evaluating an Asian CDMO for a US or EU program should cross-check with the US region ranking and Europe region ranking — CDMOs appearing across regions have demonstrated multi-jurisdictional posture.
Recent US regulatory events affecting Asian CDMO selection (WuXi 1260H, BioSecure Act considerations)
Asian CDMOs — particularly Chinese-headquartered players — are subject to US regulatory events that affect sponsor risk assessment. The US Department of Defense's 1260H list (which added WuXi AppTec in June 2026) and the BioSecure Act (proposed federal legislation restricting federally-funded research and Medicare/Medicaid drug programs from working with named Chinese biotech companies) are both active considerations. CDMO Signal's platform does not encode US political risk into the Signal Score directly — the composite reflects regulatory quality, operations, financial stability, and capacity signals. Sponsors weighing an Asian CDMO for a US-supplying program should evaluate US regulatory risk separately as a distinct decision layer alongside the Signal Score-based capability assessment.
Cell & Gene Therapy CDMOs — Frequently Asked Questions
Who are the top Cell & Gene Therapy CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Cell & Gene Therapy CDMOs include AGC Biologics, Pharmaron Biologics, Ajinomoto Bio-Pharma Services. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Cell & Gene Therapy CDMOs have FDA inspection records?
CDMO Signal tracks 7 Cell & Gene Therapy CDMOs with FDA inspection records and 41 EMA/MHRA GMP certificates across the group.
What should I look for in a cell and gene therapy CDMO?
Start with process class match — cell therapy vs vector vs both. For ex vivo programs benefit from integrated CDMOs. Verify inspection record on the specific process class, confirm capacity match to your patient volume, and prioritize CDMOs with commercial-scale posture for late-stage work.
How many cell and gene therapy CDMOs does CDMO Signal track?
109 CDMOs are tracked as cell or gene therapy manufacturers — the union of cell therapy, AAV, lentiviral, adenoviral, and gene therapy-tagged CDMOs. This is the broadest advanced-therapy candidate list on our platform.
Related modalities